Edith Cowan University (ECU) researchers have developed the world’s first blood test capable of detecting melanoma in its early stages, a breakthrough that will save thousands of lives, as well as millions of dollars for the health system.
In a trial involving 105 people with melanoma and 104 healthy controls, the blood test was able to detect early stage melanoma in 79 per cent of cases.
Australia has the second highest rate of melanoma in the world, with 14,000 new diagnoses and almost 2000 deaths each year.
Lead researcher PhD candidate Pauline Zaenker said identifying melanoma early was the best way to preventing these deaths.
“Patients who have their melanoma detected in its early stage have a five year survival rate between 90 and 99 per cent, whereas if it is not caught early and it spreads around the body, the five year survival rate drops to less than 50 per cent,” she said.
“This is what makes this blood test so exciting as a potential screening tool because it can pick up melanoma in its very early stages when it is still treatable.”
Currently the main way melanoma is detected is by a visual scan by a clinician with any areas of skin that are of concern excised and sent for a biopsy.
Ms Zaenker, from ECU’s Melanoma Research Group (MRG), said the new blood test could provide doctors with a powerful new tool to detect melanoma before it spreads throughout the body.
“While clinicians do a fantastic job with the tools available, relying on biopsies alone can be problematic. We know that three out of four biopsies come back negative for melanoma,” she said.
“The biopsies are quite invasive, with a minimum of 1cm by 1cm of skin excised from the patient.
“They are also costly, with previous research showing that the Australian health system spends $201 million on melanoma each year with an additional $73 million on negative biopsies.”
Antibodies provide early warning
The blood test works by detecting the autoantibodies the body produces in response to the melanoma.
“The body starts producing these antibodies as soon as melanoma first develops which is how we have been able to detect the cancer in its very early stages with this blood test. No other type of biomarker appears to be capable of detecting the cancer in blood at these early stages.” Ms Zaenker said.
“We examined a total of 1627 different types of antibodies to identify a combination of 10 antibodies that best indicated the presence of melanoma in confirmed patients relative to healthy volunteers.”
MelanomaWA Chief Executive Officer Clinton Heal knows first-hand the importance of developing new ways to detect skin cancer – he has had 34 secondary tumours removed since he was diagnosed with melanoma at the age of 22.
“At MelanomaWA we see first-hand the importance of early detection and how it’s critical to the long term survival of people diagnosed with melanoma,” he said.
“I am personally so excited to see this research transcending into clinical practice, having given of my own blood samples to the Melanoma Research Group following my diagnosis in 2005.
“My primary melanoma was not detected early, and I believe a simple blood test could have drastically improved my melanoma diagnosis and subsequent treatment since.”
MRG head Professor Mel Ziman said a follow up clinical trial to validate the findings was being organised.
“We envision this taking about three years. If this is successful we would hope to be able to have a test ready for use in pathology clinics shortly afterwards,” she said.
“The ultimate goal is for this blood test to be used to provide greater diagnostic certainty prior to biopsy and for routine screening of people who are at a higher risk of melanoma, such as those with a large number of moles or those with pale skin or a family history of the disease.”
The blood test (MelDx) has been submitted for an international patent.
Receive an email update when we add a new MELANOMA article.
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- United States Melanoma Market and Competitive Landscape Report 2019on September 6, 2019 at 3:16 pm
DUBLIN, Sept. 6, 2019 /PRNewswire/ -- The "US Melanoma Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering. The latest research, US Melanoma Market ...
- Melanoma Research Alliance Announces Nine Research Awards in Inaugural Class of Dermatology Fellowson September 4, 2019 at 7:30 am
WASHINGTON--(Business Wire)--In recognition of the critical role dermatologists can play in the prevention and early detection of melanoma, the Melanoma Research Alliance (MRA), the largest non-profit ...
- He was wounded in a mass shooting. She has melanoma. How an Aurora cop and his wife are leaning on each other.on September 3, 2019 at 7:42 am
From his hospital bed, Aurora police officer John Cebulski wondered if doctors could bandage his knee so he could make it to his son’s senior night basketball game. Cebulski had been shot in the leg ...
- After Biotech Dives Deeper Into Melanoma Data, It 'Continues to Impress'on August 30, 2019 at 9:23 pm
August 29, 2019 (Investorideas.com Newswire) Details from this clinical program are discussed, along with Q2/19 earnings and the next stock catalyst, in an H.C. Wainwright & Co. report. In an Aug ...
- Immunotherapy vs BRAF/MEK Inhibitors in the Adjuvant Setting for Melanomaon August 30, 2019 at 10:32 am
At the recent ASCO annual meeting in Chicago, Janice Mehnert, MD, of Rutgers Cancer Institute of New Jersey, spoke with MedPage Today about immune checkpoint and BRAF/MEK therapy for patients, and the ...
- Media Advisory - Save Your Skin Launches Inaugural “Move For Melanoma” Challenge Benefiting Skin Cancer Patients Across Canadaon August 29, 2019 at 10:10 pm
VANCOUVER, British Columbia, Aug. 30, 2019 (GLOBE NEWSWIRE) -- On Friday, September 13 th Save Your Skin Foundation will officially launch the 2019 Move for Melanoma Challenge. The unique campaign ...
- 2001 to 2016 saw large increase in Mohs surgery for melanomaon August 29, 2019 at 10:03 am
(HealthDay)—From 2001 to 2016, the use of Mohs surgery for melanoma increased more than threefold, according to a study published online Aug. 28 in JAMA Dermatology. Michael P. Lee, from Eastern ...
- Use of Mohs Surgery for Melanoma Tx on the Riseon August 28, 2019 at 3:39 pm
Use of Mohs surgery, with and without immunohistochemistry, to treat melanoma is growing, although there is some geographic variation in surgical practices, a national cross-sectional analysis found.
- Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lineson August 28, 2019 at 2:07 am
Malignant melanoma remains the most aggressive and treatment-resistant form of skin cancer with increasing incidence 1. Although recent advances in melanoma therapy improve the overall patient ...
via Bing News